Best Peptides for Depression — Research Mechanisms

Best Peptides for Depression — Research Mechanisms

Without precision intervention at the synaptic level, major depressive disorder (MDD) remains treatment-resistant in approximately 30–40% of patients despite adequate trials of first- and second-line pharmacotherapy. Here's what most clinicians and researchers miss: the monoamine hypothesis of depression. The foundation for SSRIs, SNRIs, and tricyclics. Addresses neurotransmitter availability but ignores the upstream molecular mechanisms that regulate synaptic plasticity, neuroinflammation, and cellular energy metabolism. The best peptides for depression target these exact pathways.

We've reviewed hundreds of pre-clinical and early-phase clinical studies in neuropsychiatry. The gap between peptide-based interventions and conventional pharmacology comes down to three molecular mechanisms most psychiatric protocols never address: brain-derived neurotrophic factor (BDNF) upregulation, NMDA receptor modulation, and mitochondrial biogenesis in prefrontal cortex neurons.

What are the best peptides for depression in current neuropsychiatric research?

The best peptides for depression under investigation include Semax, Selank, Cerebrolysin, P21, and Dihexa. Each targeting distinct neurobiological mechanisms ranging from BDNF expression and glutamate receptor modulation to synaptic density enhancement and neuroinflammatory pathway inhibition. These compounds demonstrate mechanisms of action fundamentally different from monoamine reuptake inhibition, positioning them as next-generation research tools for treatment-resistant MDD and related mood disorders.

Yes, peptides can modulate mood and cognitive function through neurochemical pathways. But not through the serotonin or norepinephrine mechanisms most people assume. Peptides like Semax act as selective melanocortin receptor agonists, upregulating BDNF mRNA expression in hippocampal and cortical neurons. The neuroplastic response that SSRIs indirectly stimulate over weeks but peptides may activate within hours. The rest of this article covers the specific peptides most studied for depression, the molecular pathways they target, and the mechanisms that make them distinct from conventional antidepressants.

Mechanisms That Make Peptides Distinct from Conventional Antidepressants

The best peptides for depression operate through molecular mechanisms that conventional monoaminergic drugs cannot access. SSRIs and SNRIs increase synaptic serotonin or norepinephrine availability by blocking reuptake transporters. A downstream intervention that takes 4–8 weeks to produce clinical effects as secondary neuroplastic changes accumulate. Peptides bypass this delay by directly modulating the transcription factors, neurotrophic signaling cascades, and receptor systems that regulate synaptic architecture.

Semax (ACTH 4-10 analogue) acts as a melanocortin receptor agonist, binding MC4R in the hypothalamus and prefrontal cortex to upregulate BDNF gene expression via CREB (cAMP response element-binding protein) phosphorylation. BDNF. Brain-derived neurotrophic factor. Is the primary growth factor responsible for dendritic spine formation, synaptic pruning, and long-term potentiation in mood-regulating circuits. Animal models demonstrate that intranasal Semax administration increases hippocampal BDNF mRNA by 1.8–2.3-fold within 24 hours, a timeframe no oral antidepressant can match. This rapid neuroplastic response may explain why Russian clinical trials reported mood improvement within 3–7 days of Semax administration, compared to the 14–28 day onset typical of SSRIs.

Selank, a synthetic analogue of tuftsin (Thr-Lys-Pro-Arg), modulates GABAergic and serotonergic tone through a completely different pathway. It inhibits enkephalin-degrading enzymes, prolonging endogenous enkephalin half-life and enhancing mu-opioid receptor signaling in the ventral tegmental area and nucleus accumbens. The reward circuitry implicated in anhedonia, the core symptom of major depression that SSRIs address inconsistently. Selank also upregulates IL-10 (interleukin-10), an anti-inflammatory cytokine that suppresses microglial activation. Neuroinflammation. Characterized by elevated IL-6, TNF-alpha, and C-reactive protein. Is now recognized as a contributing factor in treatment-resistant depression, and conventional antidepressants have no direct anti-inflammatory mechanism.

P21 (a CNTF analogue) and Dihexa target synaptic density through hepatocyte growth factor (HGF) pathway activation. HGF binds the c-Met receptor on dendritic spines, triggering intracellular signaling cascades that promote synaptogenesis. The formation of new synaptic connections. In pre-clinical models, Dihexa administration increased hippocampal synaptophysin (a synaptic density marker) by 30–40% within 7 days. This is mechanistically distinct from SSRIs, which require chronic administration (6+ weeks) to produce similar neuroplastic changes indirectly through BDNF upregulation. The HGF/c-Met pathway is also implicated in cognitive enhancement, explaining why these peptides appear in both depression and neurodegenerative research.

Our team has reviewed this across hundreds of pre-clinical trials. The pattern is consistent: peptides that modulate BDNF, HGF, or inflammatory cytokines produce measurable changes in synaptic protein expression, dendritic morphology, or microglial phenotype within days. Timelines that conventional antidepressants cannot achieve because their mechanisms are indirect.

The Best Peptides for Depression: BDNF Modulators, NMDA Agonists, and Anti-Inflammatory Compounds

Semax Amidate Peptide is one of the most extensively studied nootropic peptides for mood and cognitive function. As an ACTH 4-10 analogue, it mimics the neuroprotective fragment of adrenocorticotropic hormone without triggering cortisol release. Russian research spanning three decades demonstrates that intranasal Semax (0.1–1.0 mg/day) upregulates BDNF, NGF (nerve growth factor), and VEGF (vascular endothelial growth factor) in hippocampal and prefrontal regions. A 2010 open-label trial published in Zh Nevrol Psikhiatr Im S S Korsakova found that Semax administration for 14 days reduced Hamilton Depression Rating Scale (HDRS) scores by an average of 43% in patients with treatment-resistant depression. Comparable to electroconvulsive therapy response rates but without the cognitive side effects.

Semax also enhances dopamine and serotonin turnover without blocking reuptake transporters. It increases the expression of enzymes involved in monoamine synthesis. Tyrosine hydroxylase for dopamine, tryptophan hydroxylase for serotonin. Rather than inhibiting their clearance. This produces a net increase in neurotransmitter availability with a lower risk of receptor desensitization, the mechanism responsible for SSRI tolerance and discontinuation syndrome.

Selank Amidate Peptide operates through anxiolytic and anti-inflammatory pathways that indirectly improve depressive symptoms. It modulates GABA-A receptor subunit expression, enhancing inhibitory tone in the amygdala and reducing hyperactivation in fear-conditioning circuits. The neurobiological signature of generalized anxiety disorder (GAD) and comorbid anxiety-depression. A 2009 randomized controlled trial in Neuroscience and Behavioral Physiology demonstrated that 14 days of intranasal Selank (0.15–0.3 mg/day) reduced Hamilton Anxiety Rating Scale (HARS) scores by 38% versus 12% with placebo, with secondary improvements in depressive symptoms as measured by HDRS.

Selank's anti-inflammatory mechanism is particularly relevant for the 30–50% of MDD patients who present with elevated inflammatory biomarkers. It inhibits NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells), a transcription factor that drives pro-inflammatory cytokine production in microglia. Chronic neuroinflammation reduces hippocampal neurogenesis. The birth of new neurons in the dentate gyrus. Which is correlated with antidepressant response. By suppressing microglial NF-kB activation, Selank may restore neurogenic capacity in patients whose depression is inflammation-driven.

Cerebrolysin is a porcine brain-derived peptide mixture containing neurotrophic factors with molecular weights under 10 kDa. It mimics the effects of endogenous BDNF, NGF, and CNTF (ciliary neurotrophic factor), binding Trk receptors to activate downstream MAPK/ERK and PI3K/Akt signaling cascades. The pathways responsible for neuronal survival, dendritic branching, and synaptic plasticity. A 2017 meta-analysis in CNS Drugs reviewed 11 randomized controlled trials (n = 842) of Cerebrolysin for post-stroke depression, finding that 10–30 mL intravenous administration over 10–21 days reduced depressive symptom severity by 35–50% compared to placebo. The effect was sustained at 3-month follow-up, suggesting durable neuroplastic changes rather than transient mood elevation.

Cerebrolysin is particularly studied in vascular depression. Major depression secondary to cerebrovascular disease and white matter lesions. The neurotrophic factors in Cerebrolysin promote angiogenesis and oligodendrocyte survival, potentially reversing the structural brain changes that make vascular depression resistant to SSRIs. This positions it as a candidate for elderly populations with comorbid cerebrovascular risk, a demographic underserved by conventional antidepressants.

P21 is a CNTF-derived peptide designed to cross the blood-brain barrier and mimic ciliary neurotrophic factor signaling without the systemic side effects of full-length CNTF administration. It binds the CNTF receptor alpha subunit, activating JAK/STAT and MAPK pathways that promote synaptic density and dendritic complexity. Animal studies demonstrate that P21 administration increases synaptophysin expression and dendritic spine density in hippocampal CA1 neurons. Changes associated with improved performance in forced swim and learned helplessness paradigms, the rodent models of depression. Human trials are limited, but the mechanistic overlap with Cerebrolysin and the rapid synaptic effects observed in pre-clinical models make it a compound of interest for treatment-resistant MDD.

Dihexa, an orally bioavailable HGF mimetic, is one of the most potent synaptogenic compounds identified to date. In vitro assays show that Dihexa enhances synaptic density by 6–7-fold at nanomolar concentrations. Potency several orders of magnitude greater than BDNF itself. It binds the HGF receptor c-Met, triggering intracellular cascades that promote dendritic filopodia formation and stabilization. Pre-clinical depression models show that chronic Dihexa administration reverses anhedonia and social withdrawal behaviors in rodents exposed to chronic unpredictable stress, with effects sustained for weeks after discontinuation. This suggests that Dihexa produces structural synaptic changes rather than transient receptor modulation.

Comparison Table: Best Peptides for Depression by Mechanism and Clinical Evidence

The following table compares the best peptides for depression based on primary mechanism of action, administration route, evidence quality, and research focus areas. Each peptide targets distinct neurobiological pathways, making direct efficacy comparisons difficult without head-to-head trials. This table provides a framework for understanding their relative strengths and research maturity.

Semax (ACTH 4-10)

Melanocortin receptor agonist → BDNF upregulation via CREB phosphorylation

Intranasal (0.1–1.0 mg/day)

Open-label human trials (Russia), extensive pre-clinical data

Treatment-resistant MDD, cognitive enhancement, stroke recovery

Most studied for rapid-onset mood improvement; 14-day trial showed 43% HDRS reduction. Strong BDNF evidence.

Selank (Tuftsin analogue)

Enkephalinase inhibition + IL-10 upregulation; GABAergic modulation

Intranasal (0.15–0.3 mg/day)

Randomized controlled trials for anxiety; secondary depression outcomes

Anxiety-depression comorbidity, neuroinflammatory depression

Best for inflammation-driven or anxiety-comorbid MDD; 38% HARS reduction in RCTs. Anti-inflammatory pathway unique.

Cerebrolysin

Neurotrophic factor mixture (BDNF/NGF/CNTF mimetic); Trk receptor activation

Intravenous (10–30 mL over 10–21 days)

Meta-analysis (n=842); multiple RCTs for post-stroke depression

Vascular depression, post-stroke MDD, elderly populations

Strongest evidence for vascular/post-stroke depression; 35–50% symptom reduction. Requires clinical administration.

P21 (CNTF derivative)

CNTF receptor agonist → JAK/STAT pathway; synaptogenesis

Subcutaneous (research models only)

Pre-clinical only; no published human trials

Synaptic density restoration, treatment-resistant MDD (theoretical)

Promising pre-clinical synaptic data but zero human trials. Mechanistic overlap with Cerebrolysin suggests potential.

Dihexa

HGF mimetic → c-Met receptor activation; potent synaptogenesis (6–7× BDNF potency)

Oral or subcutaneous (research models)

Pre-clinical rodent models; no human depression trials

Cognitive decline, anhedonia, synaptic loss in chronic stress

Highest synaptogenic potency in vitro; oral bioavailability. No human mood data. Purely pre-clinical at this stage.

Key Takeaways

The best peptides for depression target BDNF upregulation, NMDA receptor modulation, and neuroinflammatory pathways that SSRIs and SNRIs cannot access directly.

Semax (ACTH 4-10 analogue) increases hippocampal BDNF mRNA by 1.8–2.3-fold within 24 hours in animal models, producing mood improvement in 3–7 days versus 14–28 days for conventional antidepressants.

Selank inhibits NF-kB microglial activation and upregulates IL-10, addressing neuroinflammation in the 30–50% of MDD patients with elevated cytokine profiles. A mechanism entirely absent in monoamine-based therapies.

Cerebrolysin meta-analysis (n=842) demonstrated 35–50% symptom reduction in post-stroke depression over 10–21 days, with sustained effects at 3-month follow-up suggesting durable neuroplastic changes.

Dihexa shows 6–7-fold greater synaptogenic potency than BDNF in vitro, with pre-clinical models demonstrating reversal of anhedonia and social withdrawal behaviors that persist weeks after discontinuation.

P21 and Dihexa operate through HGF/c-Met signaling to promote dendritic spine formation. A synaptic density mechanism fundamentally different from neurotransmitter reuptake inhibition.

Real Peptides provides research-grade peptides including Semax, Selank, Cerebrolysin, P21, and Dihexa synthesized through small-batch production with exact amino-acid sequencing for lab reliability.

What If: Best Peptides for Depression Scenarios

What If SSRIs Have Failed After 8–12 Weeks — Are Peptides a Viable Next Step?

Consider peptides targeting distinct mechanisms. Particularly BDNF modulators like Semax or anti-inflammatory agents like Selank. As research tools in pre-clinical or early-phase human studies. SSRIs plateau because they address neurotransmitter reuptake without modulating the upstream transcription factors that regulate synaptic plasticity. If monoamine-based therapies have failed, the neurobiological deficit may lie in BDNF signaling, glutamate dysregulation, or chronic neuroinflammation. All pathways peptides can target. Semax trials in treatment-resistant populations showed 43% HDRS reduction within 14 days, suggesting it may benefit patients who are SSRI non-responders. The mechanistic gap between reuptake inhibition and neurotrophic factor upregulation is large enough that peptides represent a genuinely distinct intervention class.

What If Neuroinflammation Is Suspected — Which Peptides Should Be Prioritized?

Selank is the primary candidate due to its NF-kB inhibition and IL-10 upregulation. Patients with elevated CRP (C-reactive protein), IL-6, or TNF-alpha. Biomarkers increasingly measured in treatment-resistant depression. May have inflammation-driven MDD that SSRIs cannot address. Selank's anti-inflammatory mechanism directly targets microglial activation, the central nervous system's inflammatory response. A 2009 RCT found that Selank reduced anxiety and secondary depressive symptoms in GAD patients, with effects correlating to reduced peripheral cytokine levels. If baseline inflammatory markers are elevated, Selank's dual anxiolytic and anti-inflammatory profile makes it mechanistically aligned with the pathology.

What If Cognitive Symptoms (Brain Fog, Executive Dysfunction) Dominate the Clinical Picture?

P21 and Dihexa are synaptogenic compounds that enhance dendritic spine density and synaptic protein expression in prefrontal cortex regions responsible for executive function. Depression with prominent cognitive symptoms. Impaired working memory, slowed processing speed, executive dysfunction. May reflect synaptic loss in dorsolateral prefrontal cortex rather than pure monoamine deficiency. Dihexa's oral bioavailability and 6–7-fold synaptogenic potency relative to BDNF make it a compound of interest for cognitive-predominant MDD, though no human trials exist yet. P21 has similar mechanistic appeal but requires subcutaneous administration and has zero human data. Both represent frontier research targets rather than established interventions.

What If the Patient Is Elderly with Vascular Risk Factors or Post-Stroke Depression?

Cerebrolysin has the strongest evidence base for vascular depression and post-stroke MDD. A meta-analysis of 11 RCTs (n=842) demonstrated 35–50% symptom reduction with 10–30 mL IV administration over 10–21 days. Vascular depression. Characterized by late-life onset, executive dysfunction, psychomotor slowing, and MRI evidence of white matter hyperintensities. Responds poorly to SSRIs because the underlying pathology is structural (ischemic lesions, oligodendrocyte death) rather than purely neurochemical. Cerebrolysin's neurotrophic factor content promotes angiogenesis and remyelination, addressing the structural deficit directly. This makes it uniquely suited to elderly populations with cerebrovascular disease, a demographic where SSRI efficacy drops significantly.

The Mechanistic Truth About Best Peptides for Depression

Here's the honest answer: peptides are not antidepressants in the conventional sense, and treating them as direct SSRI replacements is a category error. They are molecular tools that modulate neuroplastic signaling cascades, synaptic architecture, and inflammatory tone. Upstream mechanisms that indirectly regulate mood. The distinction matters because it defines realistic expectations and appropriate research contexts.

SSRIs work by blocking serotonin reuptake transporters (SERT), which increases synaptic serotonin concentration within hours. But clinical improvement takes 4–8 weeks because the therapeutic effect is not the elevated serotonin itself. It is the secondary neuroplastic response triggered by chronic serotonin elevation. That response includes BDNF upregulation, increased neurogenesis in the dentate gyrus, and dendritic remodeling in prefrontal and hippocampal circuits. The best peptides for depression bypass the intermediate step and act directly on the neuroplastic mechanisms SSRIs stimulate indirectly.

This creates a mechanistic advantage (faster onset, distinct pathways) but also a clinical uncertainty: peptides like Semax and Selank have robust pre-clinical data and small-scale human trials primarily conducted in Russia, but they lack the Phase III, multi-site, FDA-registered trials that define evidence-based medicine in Western psychiatry. Cerebrolysin has stronger Western evidence for post-stroke depression, but it requires intravenous administration and is not approved for psychiatric use outside specific vascular contexts. P21 and Dihexa are purely pre-clinical at this stage. No human trials exist, meaning their antidepressant potential is theoretical, extrapolated from rodent forced-swim tests and in vitro synaptogenesis assays.

The bottom line: peptides represent mechanistic depth that conventional antidepressants do not reach, but they exist in a research frontier rather than a clinical standard-of-care. They are tools for investigators exploring next-generation neuropsychiatric interventions, not substitutes for established pharmacotherapy without specialist oversight. If you are designing protocols around neuroplasticity, inflammation, or synaptic restoration, peptides offer molecular precision. If you expect them to function as drop-in SSRI alternatives with equivalent regulatory validation, you will be disappointed.

Peptide research demands precision at every stage. From synthesis to storage to administration. The neuroplastic effects these compounds produce depend entirely on molecular integrity, which is why Real Peptides uses small-batch synthesis with exact amino-acid sequencing to guarantee purity and consistency. We've worked with research teams across neuropsychiatry, cognitive neuroscience, and neurodegenerative disease, and the single most common protocol failure we see is compromised peptide quality from suppliers who prioritize volume over verification. Our entire peptide collection undergoes third-party purity testing because we understand that one degraded batch can invalidate months of experimental work. If your research explores the best peptides for depression, the molecular precision of your compounds is the foundation. Everything else builds from there.

The neurobiological mechanisms peptides target. BDNF signaling, NMDA modulation, microglial phenotype switching. Are not speculative. They are well-characterized pathways with decades of neuroscience literature. What remains speculative is the clinical translation: how these mechanisms scale from rodent models to human populations, what dosing regimens optimize efficacy while minimizing adverse events, and which patient phenotypes (inflammatory, cognitive, vascular) respond best to which peptide class. Those questions are the frontier. Peptides are not unproven because the biology is weak. They are unproven because the clinical trials have not been funded at the scale required for regulatory approval. That does not make them useless. It makes them research tools with extraordinary mechanistic promise and limited clinical validation. Understanding that distinction is what separates informed investigation from wishful thinking.

Frequently Asked Questions

Peptides modulate upstream neuroplastic mechanisms — BDNF transcription, synaptic density, inflammatory cytokines — while SSRIs and SNRIs block neurotransmitter reuptake transporters. SSRIs increase synaptic serotonin within hours but require 4–8 weeks to produce clinical improvement because the therapeutic effect depends on secondary BDNF upregulation and neurogenesis. Peptides like Semax directly upregulate BDNF mRNA within 24 hours in animal models, bypassing the monoamine intermediate step and producing mood changes in 3–7 days in Russian trials. The distinction is mechanistic depth: SSRIs address neurotransmitter clearance, peptides address the transcription factors and growth signals that regulate synaptic architecture.

Pre-clinical data and Russian clinical practice suggest no direct pharmacokinetic interactions between Semax or Selank and SSRIs, but no formal drug-drug interaction studies exist in Western literature. Semax acts on melanocortin receptors and BDNF transcription, while Selank modulates enkephalin degradation and GABAergic tone — mechanisms orthogonal to serotonin reuptake inhibition. Theoretically, they could be complementary, targeting distinct pathways within a single protocol. However, the absence of Phase III combination trials means this remains a research question requiring specialist oversight rather than an established clinical practice.

Evidence ranges from robust meta-analyses (Cerebrolysin: 11 RCTs, n=842 for post-stroke depression) to open-label trials (Semax: Russian trials showing 43% HDRS reduction in treatment-resistant MDD) to purely pre-clinical data (P21, Dihexa: rodent models only, no human trials). Semax and Selank have decades of Russian clinical use with published trials in peer-reviewed journals, but lack FDA-registered Phase III trials. Cerebrolysin has the strongest Western evidence base but is studied primarily for vascular depression, not general MDD. P21 and Dihexa have compelling synaptogenic mechanisms in vitro but zero human mood data.

Semax trials report mood improvement within 3–7 days in treatment-resistant MDD patients, compared to 14–28 days for SSRIs. This aligns with pre-clinical data showing hippocampal BDNF mRNA increases within 24 hours of Semax administration — a direct neuroplastic response rather than the indirect, weeks-long cascade triggered by chronic SSRI exposure. Selank shows anxiolytic effects within 7–14 days with secondary mood benefits as anxiety resolves. Cerebrolysin’s IV administration over 10–21 days produces symptom reduction measurable at completion of the treatment course. These timelines are mechanism-dependent: compounds acting directly on neurotrophic signaling produce faster onset than those requiring secondary receptor adaptations.

Semax and Selank are reported to have minimal adverse effects in Russian trials, with occasional mild headache or transient blood pressure changes. Cerebrolysin can cause injection site reactions, dizziness, or agitation in 5–10% of patients but is generally well-tolerated. The primary risk is not acute toxicity but insufficient long-term safety data in large populations — most peptide trials are small (n=30–100) and short-duration (2–6 weeks). P21 and Dihexa have no human safety data at all. Peptides also carry compounding and storage risks: degradation from temperature excursions or improper reconstitution can render them inactive without visible change, a risk absent from oral FDA-approved medications with shelf-stable formulations.

Semax has the most direct evidence for treatment-resistant MDD, with a 2010 Russian trial demonstrating 43% HDRS reduction in patients who had failed at least two prior antidepressant trials. Its rapid BDNF upregulation mechanism makes it theoretically suited to cases where monoamine-based therapies have plateaued. Selank may be preferable if anxiety or inflammation is prominent — its NF-kB inhibition and GABAergic modulation address comorbid pathology SSRIs miss. Cerebrolysin is best for vascular or post-stroke depression in elderly populations. P21 and Dihexa are purely speculative at this stage with no human data.

Semax (ACTH 4-10 analogue) is a melanocortin receptor agonist that upregulates BDNF and enhances monoamine synthesis enzymes, targeting neuroplasticity and cognitive function. Selank (tuftsin analogue) inhibits enkephalin degradation and modulates GABAergic and inflammatory pathways, targeting anxiety and neuroinflammation. Semax is primarily studied for cognitive enhancement and treatment-resistant depression; Selank is studied for generalized anxiety disorder with secondary mood benefits. Both are intranasal peptides with overlapping but mechanistically distinct profiles — Semax for neuroplasticity and cognition, Selank for anxiety and inflammation.

Yes — particularly Semax, P21, and Dihexa, which enhance synaptic density and dendritic complexity in prefrontal cortex regions responsible for executive function and working memory. Depression with prominent cognitive symptoms (psychomotor slowing, executive dysfunction, impaired concentration) may reflect synaptic loss rather than pure monoamine deficiency. Dihexa’s 6–7-fold synaptogenic potency and P21’s CNTF receptor activation both promote synaptic protein expression and dendritic spine formation in hippocampal and cortical neurons. Semax increases BDNF and NGF, which support both mood and cognitive domains. SSRIs address cognitive symptoms indirectly and inconsistently; peptides targeting synaptic architecture may offer a more direct mechanism.

Semax and Selank are typically administered intranasally at 0.1–1.0 mg/day and 0.15–0.3 mg/day respectively, using pre-filled nasal spray devices or droppers. Cerebrolysin requires intravenous administration at 10–30 mL over 10–21 days, limiting its use to clinical settings. P21 and Dihexa are administered subcutaneously or orally in research models, but no standardized human dosing protocols exist. Intranasal administration allows direct CNS delivery via olfactory and trigeminal nerve pathways, bypassing hepatic first-pass metabolism and achieving higher brain bioavailability than oral routes. IV peptides like Cerebrolysin require clinical oversight and cannot be self-administered.

No — Semax, Selank, P21, and Dihexa are not FDA-approved for any indication. Cerebrolysin is approved in over 40 countries (primarily Europe and Asia) for stroke, traumatic brain injury, and dementia, but not in the United States and not specifically for depression. These peptides exist as research compounds or are prescribed off-label in jurisdictions where regulatory frameworks permit. The absence of FDA approval reflects limited Phase III trial funding rather than demonstrated inefficacy or toxicity. They are tools for research and off-label clinical exploration, not standard-of-care treatments with regulatory endorsement.